On December 13, Guanglonghui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary, Hainan Lionco Pharmaceutical Co., Ltd., participated in the 10th national centralized procurement organized by the National Organization for Pharmaceutical Joint Procurement Office (referred to as "Joint Procurement Office"). According to the public announcement of the proposed selection results for national centralized procurement released by the Joint Procurement Office, Lionco Pharmaceutical's injectable ceftiofur sodium is proposed to be selected for this centralized procurement. The sales of injectable ceftiofur sodium by the company's wholly-owned subsidiary Lionco Pharmaceutical amounted to 0 million yuan in 2023, accounting for 0% of the company's revenue for 2023; the sales for the first three quarters of 2024 were 3.2067 million yuan, accounting for 1.39% of the company's revenue for the first three quarters of 2024.
灵康药业(603669.SH)：子公司参与全国药品集中采购拟中选
Lionco Pharmaceutical Group (603669.SH): Subsidiary participates in the national pharmaceutical centralized procurement and plans to be selected.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated